Drug Profile


Alternative Names: EMD 1195686; FCE 26743; ME 2125; NW 1015; PNU 151774; PNU 151774E; Safinamide mesilate; Safinamide mesylate; Xadago; ZP-034

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer Meiji Seika Pharma; Newron Pharmaceuticals; US WorldMeds; Zambon SpA
  • Class Amides; Antidementias; Antiepileptic drugs; Antiparkinsonians; Benzylamines; Fluorobenzenes; Neuroprotectants; Small molecules
  • Mechanism of Action Calcium channel antagonists; Dopamine uptake inhibitors; Glutamate-release-inhibitors; Monoamine oxidase B inhibitors; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Parkinson's disease
  • No development reported Drug-induced dyskinesia
  • Discontinued Alzheimer's disease; Epilepsy; Restless legs syndrome

Most Recent Events

  • 11 Jul 2017 Launched for Parkinson's disease (Adjunctive treatment) in USA (PO)
  • 11 Apr 2017 Safinamide licensed to Valeo Pharma in Canada
  • 10 Apr 2017 Launched for Parkinson's disease (Adjunctive treatment, Combination therapy, Late-stage disease, Mid-stage disease) in Portugal (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top